Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab vedotin in advanced solid tumors and non-small cell lung cancer
NL-OMON51611Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2023
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of telisotuzumab vedotin and osimertinib in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms (2 arms), sponsored by AbbVie Inc. Primary endpoints: Safety and tolerability, Pharmacokinetics of Teliso-V, Total ABT-700, and free MMAE and 1 more. Started Jan 2023; status: active, not recruiting.
02
Drugs
telisotuzumab vedotinosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON51611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51611.